Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
February 06 2019 - 7:30AM
Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company
dedicated to the development of innovative therapeutics for
neurotology, today announced multiple presentations at the upcoming
Association for Research in Otolaryngology (ARO) 42nd Annual
MidWinter Meeting, to be held February 9-13, in Baltimore.
“Our multiple presentations at ARO demonstrate our broad
pipeline in neurotology with data presented in support of our
product candidates for Ménière’s disease, tinnitus, hearing loss
and otoprotection," said Kathie Bishop, Ph.D., chief scientific
officer of Otonomy. "In particular, we are pleased to present
information on our clinical program for OTO-313, including the
Phase 1/2 clinical trial in tinnitus patients to be initiated next
quarter, and preclinical data related to our OTO-510 program for
otoprotection that will initially focus on the prevention of
cisplatin-induced hearing loss (CIHL) in children."
Otonomy's presentation related to the OTO-313 program for
tinnitus is as follows:
- "Clinical development of intratympanic, sustained-exposure
formulation of the NMDA receptor antagonist gacyclidine for the
treatment of tinnitus" by Anderson et al., podium presentation on
February 13 at 12:15 p.m. EST
Presentations related to the OTO-510 program for CIHL
include:
- "Characterization of in-vivo rodent models of cisplatin-induced
hearing loss - acute and chronic administration paradigms" by Piu
et al., poster presentation on February 9 beginning at 1 p.m.
EST
- "Comparison of the otoprotective profiles of antioxidant and
anti-apoptotic compounds in ex vivo models of cisplatin-induced
hearing loss" by Mathur et al., poster presentation on February 12
beginning at 1 p.m. EST
- "Development of clinically relevant ex vivo models of
cisplatin-induced hearing loss" by Uribe et al., poster
presentation on February 12 beginning at 1 p.m. EST
Additional presentations related to Otonomy's other programs
include:
- "Inner ear pharmacokinetics and tissue distribution of the
sustained-exposure dexamethasone formulation OTIVIDEX™ in various
species - predicting drug exposure in Meniere's disease patients"
by Piu et al., poster presentation on February 11 beginning at 1
p.m. EST
- "Modified versions of NT-3 enable enhanced activation of TrkB
and TrkC responses in ex vivo models relevant to cochlear
synaptopathy" by Szobota et al., poster presentation on February 10
beginning at 1 p.m. EST
- "Evaluation of rapid decalcification methods for histological
assessment of rodent temporal bones" by Jones et al., poster
presentation on February 9 beginning at 1 p.m. EST
About Otonomy
Otonomy is a biopharmaceutical company dedicated to the
development of innovative therapeutics for otology. The company
pioneered the application of drug delivery technology to the ear in
order to develop products that achieve sustained drug exposure from
a single local administration. This approach is covered by a broad
patent estate and is being utilized to develop a pipeline of
products addressing important unmet medical needs including
Ménière’s disease, hearing loss, and tinnitus. For additional
information please visit www.otonomy.com.
Cautionary Note Regarding Forward Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements generally relate to future events
or the future financial or operating performance of Otonomy.
Forward-looking statements in this press release include, but are
not limited to, expectations regarding Otonomy’s pipeline and
programs, initiation of the Phase 1/2 clinical trial for OTO-313,
and statements by Otonomy’s chief scientific officer. Otonomy’s
expectations regarding these matters may not materialize, and
actual results in future periods are subject to risks and
uncertainties. Actual results may differ materially from those
indicated by these forward-looking statements as a result of these
risks and uncertainties, including but not limited to: Otonomy’s
limited operating history and its expectation that it will incur
significant losses for the foreseeable future; Otonomy’s ability to
obtain additional financing; Otonomy’s dependence on the regulatory
success and advancement of its product candidates; the
uncertainties inherent in the clinical drug development process,
including, without limitation, Otonomy’s ability to adequately
demonstrate the safety and efficacy of its product candidates, the
nonclinical and clinical results for its product candidates, which
may not support further development, and challenges related to
patient enrollment in clinical trials; Otonomy’s ability to obtain
regulatory approval for its product candidates; the risks of the
occurrence of any event, change or other circumstance that could
impact Otonomy’s ability to repay or comply with the terms of the
loan provided by Oxford Finance LLC; side effects or adverse events
associated with Otonomy’s product candidates; Otonomy’s ability to
successfully commercialize its product candidates, if approved;
competition in the biopharmaceutical industry; Otonomy’s dependence
on third parties to conduct nonclinical studies and clinical
trials; Otonomy’s dependence on third parties for the manufacture
of its product candidates; Otonomy’s dependence on a small number
of suppliers for raw materials; Otonomy’s ability to protect its
intellectual property related to its product candidates in the
United States and throughout the world; expectations regarding
potential market size, opportunity and growth; Otonomy’s ability to
manage operating expenses; implementation of Otonomy’s business
model and strategic plans for its business, products and
technology; and other risks. Information regarding the foregoing
and additional risks may be found in the section entitled "Risk
Factors" in Otonomy’s Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission (the "SEC") on November 5, 2018,
and Otonomy’s future reports to be filed with the SEC. The
forward-looking statements in this press release are based on
information available to Otonomy as of the date hereof. Otonomy
disclaims any obligation to update any forward-looking statements,
except as required by law.
Contacts:
Media Inquiries:SpectrumLeticia DiazVice
President202.587.2517ldiaz@spectrumscience.com
Investor Inquiries:Westwicke PartnersRobert H. UhlManaging
Director858.356.5932robert.uhl@westwicke.com
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Jul 2023 to Jul 2024